These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 29548299)

  • 1. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
    Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
    J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer.
    Pelster MS; Mott F; Lewin J
    Laryngoscope; 2020 Apr; 130(4):E140-E143. PubMed ID: 31074845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab.
    Lederhandler MH; Ho A; Brinster N; Ho RS; Liebman TN; Lo Sicco K
    J Drugs Dermatol; 2018 Jul; 17(7):807-809. PubMed ID: 30005106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
    Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
    Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
    Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
    Kumai T; Komatsuda H; Minami Y; Harabuchi Y
    ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
    Horisberger A; La Rosa S; Zurcher JP; Zimmermann S; Spertini F; Coukos G; Obeid M
    J Immunother Cancer; 2018 Dec; 6(1):156. PubMed ID: 30587227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report.
    Dang H; Sun J; Wang G; Renner G; Layfield L; Hilli J
    World J Clin Cases; 2020 Sep; 8(18):4100-4108. PubMed ID: 33024767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
    Desilets A; Soulières D
    Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
    Sheth S; Weiss J
    Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sick sinus syndrome associated with anti-programmed cell death-1.
    Hsu CY; Su YW; Chen SC
    J Immunother Cancer; 2018 Jul; 6(1):72. PubMed ID: 30012209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for the treatment of head and neck squamous cell cancer.
    Ho WJ; Mehra R
    Expert Opin Biol Ther; 2019 Sep; 19(9):879-885. PubMed ID: 31317798
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
    Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
    Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients.
    Tang AL; O'Neil T; McDermott S; Tripathi S; Tikhtman R; Mark JR; Patil Y; Tabangin M; Altaye M; Wise-Draper TM; Zender CA
    JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):935-939. PubMed ID: 36006622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.